[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609178":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":27,"centralContacts":31,"locations":37,"responsibleParty":266,"collaborators":10,"id":268,"slug":269,"hasResults":270,"nctId":271,"briefTitle":272,"officialTitle":272,"acronym":273,"eligibilityCriteria":274,"healthyVolunteers":270,"sex":275,"minAge":276,"maxAge":277,"enrollmentInfo":278,"targetDuration":10,"studyType":281,"phases":10,"briefSummary":282,"conditions":283,"keywords":289,"overallStatus":40,"whyStopped":10,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":307},{"fullName":5,"class":6},"Tempus AI","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1: Neoadjuvant Therapy",null,"There are no interventions in this observational study. Cohort 1 includes participants who will receive neoadjuvant treatment prior to surgery.",[13],"Other: There are no interventions in this observational study.",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 2: Adjuvant Therapy \u002F Surveillance","There are no interventions in this observational study. Cohort 2 includes participants who will receive adjuvant therapy after surgery.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Cohort 3: 5 Years Post-Diagnosis Surveillance","There are no interventions in this observational study. Cohort 3 includes participants who have no evidence of disease for at least 5 years post diagnosis.",[13],[23],{"type":24,"name":25,"description":25,"armGroupLabels":26,"otherNames":10},"OTHER","There are no interventions in this observational study.",[9,15,19],[28],{"name":29,"affiliation":5,"role":30},"Michelle Ting-Lin, MD","PRINCIPAL_INVESTIGATOR",[32],{"name":33,"role":34,"phone":35,"phoneExt":10,"email":36},"GEMINI Breast Clinical Study Manager","CONTACT","(833) 514-4187","gemini-breast@tempus.com",[38,58,75,91,107,122,138,154,170,186,202,218,234,250],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Birmingham Hematology Associates","RECRUITING","Birmingham","Alabama","35223","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-86.80249,33.52066,{"lat":50,"lon":49},[53,56],{"name":54,"role":34,"phone":10,"phoneExt":10,"email":55},"Amanda Joseph","Amanda.Joseph@alabamaoncology.com",{"name":57,"role":30,"phone":10,"phoneExt":10,"email":10},"Matthew Tucker",{"facility":59,"status":40,"city":60,"state":61,"zip":62,"country":44,"countryCode":45,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"PIH Health Whittier Hospital","Whittier","California","90602",{"type":47,"coordinates":64},[65,66],-118.03284,33.97918,{"lat":66,"lon":65},[69,73],{"name":70,"role":34,"phone":71,"phoneExt":10,"email":72},"Lucia Nguyen","562-698-0811","lucia.nguyen@pihhealth.org",{"name":74,"role":30,"phone":10,"phoneExt":10,"email":10},"Lisa Wang",{"facility":76,"status":40,"city":77,"state":78,"zip":79,"country":44,"countryCode":45,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Cleveland Clinic Florida","Weston","Florida","33331",{"type":47,"coordinates":81},[82,83],-80.39977,26.10037,{"lat":83,"lon":82},[86,89],{"name":87,"role":34,"phone":10,"phoneExt":10,"email":88},"Maria Dimayuga","dimayum@ccf.org",{"name":90,"role":30,"phone":10,"phoneExt":10,"email":10},"Thomas Samuel, MD",{"facility":92,"status":40,"city":93,"state":94,"zip":95,"country":44,"countryCode":45,"cosmosGeoPoint":96,"geoPoint":100,"contacts":101},"Southern Illinois Hospital Services","Carbondale","Illinois","62902",{"type":47,"coordinates":97},[98,99],-89.21675,37.72727,{"lat":99,"lon":98},[102,105],{"name":103,"role":34,"phone":10,"phoneExt":10,"email":104},"Sumita Kolay","Sumita.kolay@sih.net",{"name":106,"role":30,"phone":10,"phoneExt":10,"email":10},"Mohammad Popalzi",{"facility":108,"status":40,"city":109,"state":94,"zip":110,"country":44,"countryCode":45,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"Cancer Care Specialist of Illinois","O'Fallon","62269",{"type":47,"coordinates":112},[113,114],-89.91121,38.59227,{"lat":114,"lon":113},[117,120],{"name":118,"role":34,"phone":10,"phoneExt":10,"email":119},"Kaitlynn Knapp","kkapp@ccsci.net",{"name":121,"role":30,"phone":10,"phoneExt":10,"email":10},"James Wade",{"facility":123,"status":40,"city":124,"state":125,"zip":126,"country":44,"countryCode":45,"cosmosGeoPoint":127,"geoPoint":131,"contacts":132},"Goshen Center for Cancer Care","Goshen","Indiana","46526",{"type":47,"coordinates":128},[129,130],-85.83444,41.58227,{"lat":130,"lon":129},[133,136],{"name":134,"role":34,"phone":10,"phoneExt":10,"email":135},"Kim Neff","kneff2@goshenhealth.com",{"name":137,"role":30,"phone":10,"phoneExt":10,"email":10},"James Wheeler",{"facility":139,"status":40,"city":140,"state":141,"zip":142,"country":44,"countryCode":45,"cosmosGeoPoint":143,"geoPoint":147,"contacts":148},"Trinity Health","Ann Arbor","Michigan","48106",{"type":47,"coordinates":144},[145,146],-83.74088,42.27756,{"lat":146,"lon":145},[149,152],{"name":150,"role":34,"phone":10,"phoneExt":10,"email":151},"Christina Munson","christina.munson@trinity-health.org",{"name":153,"role":30,"phone":10,"phoneExt":10,"email":10},"Tareq Al baghdadi",{"facility":155,"status":40,"city":156,"state":157,"zip":158,"country":44,"countryCode":45,"cosmosGeoPoint":159,"geoPoint":163,"contacts":164},"Oncology Hematology Associates","Springfield","Missouri","65807",{"type":47,"coordinates":160},[161,162],-93.29824,37.21533,{"lat":162,"lon":161},[165,168],{"name":166,"role":34,"phone":10,"phoneExt":10,"email":167},"Adrianna Moore","Adrianna.Moore@aoncology.com",{"name":169,"role":30,"phone":10,"phoneExt":10,"email":10},"Roger Holden",{"facility":171,"status":40,"city":172,"state":173,"zip":174,"country":44,"countryCode":45,"cosmosGeoPoint":175,"geoPoint":179,"contacts":180},"Cancer Care Specialist of Reno","Reno","Nevada","89511",{"type":47,"coordinates":176},[177,178],-119.8138,39.52963,{"lat":178,"lon":177},[181,184],{"name":182,"role":34,"phone":10,"phoneExt":10,"email":183},"Layla Quinonez","lquinonez@ccsreno.com",{"name":185,"role":30,"phone":10,"phoneExt":10,"email":10},"Sowjanya Reganti",{"facility":187,"status":40,"city":188,"state":189,"zip":190,"country":44,"countryCode":45,"cosmosGeoPoint":191,"geoPoint":195,"contacts":196},"Summit Medical Group","Florham Park","New Jersey","07932",{"type":47,"coordinates":192},[193,194],-74.38821,40.78788,{"lat":194,"lon":193},[197,200],{"name":198,"role":34,"phone":10,"phoneExt":10,"email":199},"Michelle Mackenzie","mmackenzie@summithealth.com",{"name":201,"role":30,"phone":10,"phoneExt":10,"email":10},"Steven Parish",{"facility":203,"status":40,"city":204,"state":205,"zip":206,"country":44,"countryCode":45,"cosmosGeoPoint":207,"geoPoint":211,"contacts":212},"University of Cincinnati Medical Center","Cincinnati","Ohio","45219",{"type":47,"coordinates":208},[209,210],-84.51439,39.12711,{"lat":210,"lon":209},[213,216],{"name":214,"role":34,"phone":10,"phoneExt":10,"email":215},"Andrea Whitley","whitleal@ucmail.uc.edu",{"name":217,"role":30,"phone":10,"phoneExt":10,"email":10},"Kerri McGovern, MD",{"facility":219,"status":40,"city":220,"state":221,"zip":222,"country":44,"countryCode":45,"cosmosGeoPoint":223,"geoPoint":227,"contacts":228},"Nashville General","Nashville","Tennessee","37208",{"type":47,"coordinates":224},[225,226],-86.78444,36.16589,{"lat":226,"lon":225},[229,232],{"name":230,"role":34,"phone":10,"phoneExt":10,"email":231},"Shatika Phillips","shatika.phillips@nashvilleha.org",{"name":233,"role":30,"phone":10,"phoneExt":10,"email":10},"Robin Jacob",{"facility":235,"status":40,"city":236,"state":237,"zip":238,"country":44,"countryCode":45,"cosmosGeoPoint":239,"geoPoint":243,"contacts":244},"Cancer Care Northwest","Spokane Valley","Washington","99216",{"type":47,"coordinates":240},[241,242],-117.23937,47.67323,{"lat":242,"lon":241},[245,248],{"name":246,"role":34,"phone":10,"phoneExt":10,"email":247},"Rachel Bender","Rachel.Bender@ccnw.net",{"name":249,"role":30,"phone":10,"phoneExt":10,"email":10},"Nikolas Rademaker",{"facility":251,"status":40,"city":252,"state":253,"zip":254,"country":44,"countryCode":45,"cosmosGeoPoint":255,"geoPoint":259,"contacts":260},"Gunderson Health","La Crosse","Wisconsin","54601",{"type":47,"coordinates":256},[257,258],-91.23958,43.80136,{"lat":258,"lon":257},[261,264],{"name":262,"role":34,"phone":10,"phoneExt":10,"email":263},"Charlie Abney","charlie.abney@emplifyhealth.org",{"name":265,"role":30,"phone":10,"phoneExt":10,"email":10},"Paul Letendre",{"type":267,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100609178","evaluating-minimal-residual-disease-mrd-through-longitudinal-circulating-tumor-dna-ctdna-profiling-in-breast-malignancies-100609178",false,"NCT07211178","Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies","GEMINI Breast","Inclusion Criteria:\n\nAll Cohorts:\n\n1. Willing and able to participate in the research and provide biospecimens\n2. Willing and able to provide informed consent\n3. Must be diagnosed with breast cancer\n\nCohort 1: Neoadjuvant Treatment Cohort 1A: Newly Diagnosed, High Risk HR+,HER2-\n\n1. A known or suspected HR+, HER2- breast cancer treated with curative intent (Stage II to III disease)\n2. Patients are considered at high risk of recurrence, defined as 4 or more positive axillary lymph nodes (ALNs), or between 1-3 positive ALNs and either grade 3 disease or tumor size of 5 cm or larger.\n\nCohort 1B: HER2+ 1. A known or suspected HER2+ breast cancer treated with curative intent (Stage II to III disease). Inclusive of HR+ or HR- patients.\n\nCohort 1C: Triple Negative Breast Cancer\n\n1\\. A known or suspected triple negative breast cancer treated with curative intent (Stage I to III disease).\n\nCohort 2: Adjuvant Therapy \u002F Surveillance Cohort 2A: Newly Diagnosed HR+,HER2-\n\n1. A known or suspected HR+, HER2- breast cancer treated with curative intent (Stage II to III disease)\n2. Patients are considered at high risk of recurrence, defined as 4 or more positive axillary lymph nodes (ALNs), or between 1-3 positive ALNs and either grade 3 disease or tumor size of 5 cm or larger.\n3. Have undergone curative intent surgery with no clinical evidence of disease.\n\nCohort 2B: HER2+\n\n1. A known or suspected HER2+ breast cancer treated with curative intent (Stage II to III disease)\n2. Have undergone curative intent surgery with no clinical evidence of disease.\n\nCohort 2C: Triple Negative Breast Cancer\n\n1. A known or suspected triple negative breast cancer treated with curative intent (Stage I to III disease)\n2. Have undergone curative intent surgery with no clinical evidence of disease.\n\nCohort 3: 5-Years Post-Diagnosis Surveillance (NED)\n\n1. A known HR+, HER2- breast cancer treated with curative intent (Stage II to III disease).\n2. No Evidence of Disease (NED) ≥ 5 years from initial diagnosis.\n3. Patients are considered at high risk of recurrence, defined as 4 or more positive axillary lymph nodes (ALNs), or between 1-3 positive ALNs and either grade 3 disease or tumor size of 5 cm or larger.\n\nExclusion Criteria:\n\n1. Not willing or able to adhere with the study procedures\n2. Active secondary malignancy\n3. Diagnosis of a malignancy within 3 years of breast cancer diagnosis Note: Ductal carcinoma in situ (DCIS, ipsilateral or contralateral) within 3 years is not excluded.","ALL","18 Years","99 Years",{"count":279,"type":280},900,"ESTIMATED","OBSERVATIONAL","For patients with breast cancer, it's important to find any remaining cancer cells after they've had their main treatment. Even a few cells, called minimal residual disease (MRD), can lead to the cancer coming back later.\n\nA way to find these cells is by looking for tiny bits of cancer DNA that are shed into the blood. This is called circulating tumor DNA (ctDNA). A simple blood test, often called a liquid biopsy, can detect this ctDNA. This research aims to see if finding this cancer DNA in the blood can help predict if a patient's cancer will return. It also may help find out if the treatment is working.\n\nUltimately, the results of this research may help doctors better manage breast cancer and develop new and improved tests and treatments.",[284,285,286,287,288],"Breast Cancer","TNBC - Triple-Negative Breast Cancer","HR Positive\u002FHER-2 Negative Breast Cancer","HER2 + Breast Cancer","Early Stage Breast Cancer",[290,291,292,293,294,288,295,296,297],"Minimal Residual Disease","MRD","Next generation sequencing","NGS","ctDNA","TNBC - Triple Negative Breast Cancer","HR positive \u002F HER-2 negative breast cancer","HER2+ breast cancer","2026-06-10",{"date":300,"type":301},"2026-06-12","ACTUAL",{"date":303,"type":301},"2025-10-27",{"date":305,"type":280},"2033-12",{"name":5,"class":6},14]